|
1
|
Shaaban A and Rezvani M: Ovarian cancer:
detection and radiologic staging. Clin Obstet Gynecol. 52:73–93.
2009. View Article : Google Scholar
|
|
2
|
Chen WQ, Zhang SW, Zou XN and Zhao P:
Cancer incidence and mortality in China, 2006. Chin J Cancer Res.
23:3–9. 2011. View Article : Google Scholar
|
|
3
|
Hulett MD, Freeman C, Hamdorf BJ, Baker
RT, Harris MJ, et al: Cloning of mammalian heparanase, an important
enzyme in tumor invasion and metastasis. Nat Med. 5:803–809. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Folkman J and Shing Y: Control of
angiogenesis by heparin and other sulfated polysaccharides. Adv Exp
Med Biol. 313:355–364. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mesiano S, Ferrara N and Jaffe RB: Role of
vascular endothelial growth factor in ovarian cancer: inhibition of
ascites formation by immunoneutralization. Am J Pathol.
153:1249–1256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu S, Li Y, Chen W, Zheng P, Liu T, et
al: Silencing glypican-3 expression induces apoptosis in human
hepatocellular carcinoma cells. Biochem Biophys Res Commun.
419:656–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang G, Zheng L, Pu J, Mei H, Zhao J, et
al: Small RNAs targeting transcription start site induce heparanase
silencing through interference with transcription initiation in
human cancer cells. PLoS One. 7:e313792012. View Article : Google Scholar
|
|
8
|
Lenaerts L, van Dam W, Persoons L and
Naesens L: Interaction between mouse adenovirus type 1 and cell
surface heparan sulfate proteoglycans. PLoS One. 7:e314542012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoneda A, Lendorf ME, Couchman JR and
Multhaupt HA: Breast and ovarian cancers: a survey and possible
roles for the cell surface heparan sulfate proteoglycans. J
Histochem Cytochem. 60:9–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davies EJ, Blackhall FH, Shanks JH, David
G, McGown AT, et al: Distribution and clinical significance of
heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res.
10:5178–5186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reiland J, Sanderson RD, Waguespack M,
Barker SA, Long R, et al: Heparanase degrades syndecan-1 and
perlecan heparan sulfate: functional implications for tumor cell
invasion. J Biol Chem. 279:8047–8055. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quiros RM, Rao G, Plate J, Harris JE,
Brunn GJ, et al: Elevated serum heparanase-1 levels in patients
with pancreatic carcinoma are associated with poor survival.
Cancer. 106:532–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Moura JP Jr, Nicolau SM, Stávale JN, da
Silva Pinhal MA, de Matos LL, et al: Heparanase-2 expression in
normal ovarian epithelium and in benign and malignant ovarian
tumors. Int J Gynecol Cancer. 19:1494–1500. 2009.PubMed/NCBI
|
|
14
|
Peretti T, Waisberg J, Mader AM, de Matos
LL, da Costa RB, et al: Heparanase-2, syndecan-1, and extracellular
matrix remodeling in colorectal carcinoma. Eur J Gastroenterol
Hepatol. 20:756–765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong S and Wu XZ: Heparanase and
hepatocellular carcinoma: promoter or inhibitor? World J
Gastroenterol. 16:306–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davidson B, Shafat I, Risberg B, Ilan N,
Trope CG, et al: Heparanase expression correlates with poor
survival in metastatic ovarian carcinoma. Gynecol Oncol.
104:311–319. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inamine M, Nagai Y, Hirakawa M, Mekaru K,
Yagi C, et al: Heparanase expression in endometrial cancer:
analysis of immunohistochemistry. J Obstet Gynaecol. 28:634–637.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ginath S, Menczer J, Friedmann Y, Aingorn
H, Aviv A, et al: Expression of heparanase, Mdm2, and erbB2 in
ovarian cancer. Int J Oncol. 18:1133–1144. 2001.PubMed/NCBI
|
|
19
|
Zhang W, Yang HC, Wang Q, Yang ZJ, Chen H,
et al: Clinical value of combined detection of serum matrix
metalloproteinase-9, heparanase, and cathepsin for determining
ovarian cancer invasion and metastasis. Anticancer Res.
31:3423–3428. 2011.PubMed/NCBI
|
|
20
|
Zetser A, Bashenko Y, Miao HQ, Vlodavsky I
and Ilan N: Heparanase affects adhesive and tumorigenic potential
of human glioma cells. Cancer Res. 63:7733–7741. 2003.PubMed/NCBI
|
|
21
|
Edovitsky E, Elkin M, Zcharia E, Peretz T
and Vlodavsky I: Heparanase gene silencing, tumor invasiveness,
angiogenesis, and metastasis. J Natl Cancer Inst. 96:1219–1230.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shafat I, Ben-Arush MW, Issakov J, Meller
I, Naroditsky I, et al: Pre-clinical and clinical significance of
heparanase in Ewing's sarcoma. J Cell Mol Med. 15:1857–1864. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Z CZ, Luo C, Yang Z and Wang L: Heparanase
participates in the growth and invasion of human U-2OS osteosarcoma
cells and its close relationship with hypoxia-inducible
factor-1alpha in osteosarcoma. Neoplasma. 57:562–571.
2010.PubMed/NCBI
|
